RT Journal Article
SR Electronic
T1 Efficacy of Nitazoxanide in reducing the viral load in COVID-19 patients. Randomized, placebo-controlled, single-blinded, parallel group, pilot study.
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.03.21252509
DO 10.1101/2021.03.03.21252509
A1 Marcelo Silva
A1 Andrés Espejo
A1 María L Pereyra
A1 Martín Lynch
A1 Marcos Thompson
A1 Hernán Taconelli
A1 Patricia Baré
A1 Matías J Pereson
A1 Marcelo Garbini
A1 Pablo Crucci
A1 Diego Enriquez
YR 2021
UL http://medrxiv.org/content/early/2021/03/05/2021.03.03.21252509.abstract
AB The fast spread of COVID-19 has overcrowded Public Health Systems facilities in major countries due to the large number of seriously ill patients, particularly those requiring admission to intensive care units. Reducing viral load, along with other recommended epidemiological measures, such as social distancing and home confinement, can in time significantly help to reduce the infection R0 (Basic Reproductive Rate) and then mitigate disease burden. Early negativization or otherwise reduction of the viral load can potentially diminish disease severity, resulting in a better-controlled public health response, avoiding collapse of healthcare systems. Nitazoxanide, a widely used thiazolide approved by the FDA as an antiparasitic drug, also approved in Brazil for Norovirus and Rotavirus treatments, has an excellent safety record for a variety of indications. Nitazoxanide exhibits activity in vitro against MERS-CoV and other coronaviruses; and a specific antiviral effect (in micro molar doses) against SARS-CoV-2. The objective of this study was to evaluate the efficacy and safety of Nitazoxanide in reducing the SARS-COV 2 viral load within 7 days of treatment in respiratory samples from COVID-19-infected patients with mild to moderate disease, compared to placebo. An interim analysis showed that the ratio of patients with a viral load reduction ≥ 35% from baseline up to day 7 of treatment was significantly greater for Nitazoxanide compared to placebo (47.8% vs. 15.4%; Δ 34.6%; 95% CI: 64.7; 4.6: p = 0.037).State of the ArtDifferent studies conclude that viral load (VL) would correlate with morbidity, mortality and contagiousness of COVID-19.Early negativization or reduction of the viral load can potentially reduce the severity of this disease.In vitro data demonstrated a specific antiviral effect of Nitazoxanide for SARS-CoV-2.Article contributionNitazoxanide showed a statistically significant difference versus placebo in the number of patients who had their viral load reduced by at least 35% in mild to moderate COVID-19 disease.The observed antiviral effect in vitro would seems to be verified in patients with mild to moderate COVID-19 infection, which should be confirmed by studies with a larger cohort of patients.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04463264Funding StatementThis study was funding by Laboratorios RoemmersAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board of Facultad de Ciencias Biomedicas de la Universidad Austral.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript is available upon request https://clinicaltrials.gov/ct2/show/NCT04463264?term=Nitazoxanide&cond=Covid19&cntry=AR&draw=2&rank=1